NCT07324161 Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease
| NCT ID | NCT07324161 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fujian Medical University Union Hospital |
| Condition | Alzheimer s Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 81 participants |
| Start Date | 2025-04-16 |
| Primary Completion | 2029-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 81 participants in total. It began in 2025-04-16 with a primary completion date of 2029-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is grounded in the regulatory mechanisms of the glymphatic system and applies repetitive transcranial magnetic stimulation (rTMS) to the treatment of Alzheimer's disease (AD). The clinical efficacy and safety of rTMS will be systematically evaluated. Furthermore, transcranial magnetic stimulation-evoked potentials (TMS-EEG) and functional near-infrared spectroscopy (fNIRS) will be employed to investigate, from the perspectives of synaptic plasticity and neurovascular coupling, the mechanisms by which rTMS influences glymphatic function. Collectively, this work aims to provide new insights into both the therapeutic effectiveness and the underlying mechanisms of rTMS in AD.
Eligibility Criteria
Inclusion Criteria: * Meets the 2018 NIA-AA diagnostic criteria for Alzheimer's disease (AD) * Meets DSM-5 diagnostic criteria * Mild to moderate disease severity (CDR Global Score 1 to 2) * Evidence of AD pathology: positive amyloid PET OR positive cerebrospinal fluid (CSF) AD biomarkers OR positive plasma AD biomarkers Exclusion Criteria: * Contraindications to rTMS treatment * Severe complications or immune diseases * Unable to cooperate with study procedures * History of epilepsy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07324161 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 90 Years, studying Alzheimer s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07324161 currently recruiting?
Yes, NCT07324161 is actively recruiting participants. Contact the research team at panxd@fjmu.edu.cn for enrollment information.
Where is the NCT07324161 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07324161 clinical trial?
NCT07324161 is sponsored by Fujian Medical University Union Hospital. The trial plans to enroll 81 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.